M&T Bank Corp boosted its stake in Penumbra, Inc. (NYSE:PEN – Free Report) by 8.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,560 shares of the company’s stock after buying an additional 115 shares during the period. M&T Bank Corp’s holdings in Penumbra were worth $370,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Pallas Capital Advisors LLC raised its stake in shares of Penumbra by 3.8% in the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company’s stock worth $263,000 after buying an additional 41 shares in the last quarter. Advisors Asset Management Inc. raised its position in Penumbra by 11.5% in the third quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock worth $81,000 after acquiring an additional 43 shares in the last quarter. Pacer Advisors Inc. lifted its holdings in Penumbra by 1.0% in the 4th quarter. Pacer Advisors Inc. now owns 5,721 shares of the company’s stock valued at $1,359,000 after acquiring an additional 57 shares during the last quarter. CIBC Asset Management Inc boosted its position in shares of Penumbra by 5.4% during the 4th quarter. CIBC Asset Management Inc now owns 1,183 shares of the company’s stock valued at $281,000 after purchasing an additional 61 shares in the last quarter. Finally, UMB Bank n.a. boosted its position in shares of Penumbra by 57.4% during the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after purchasing an additional 70 shares in the last quarter. Institutional investors and hedge funds own 88.88% of the company’s stock.
Insider Activity at Penumbra
In related news, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total value of $40,293.76. Following the completion of the sale, the director now owns 8,530 shares of the company’s stock, valued at approximately $2,058,118.40. The trade was a 1.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Adam Elsesser sold 15,000 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the completion of the sale, the chief executive officer now owns 837,582 shares of the company’s stock, valued at $203,498,922.72. This represents a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,918 shares of company stock valued at $22,054,293. 5.00% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Research Report on Penumbra
Penumbra Stock Up 4.9 %
PEN stock opened at $273.51 on Friday. The company has a 50 day moving average of $269.89 and a two-hundred day moving average of $237.38. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 12-month low of $148.00 and a 12-month high of $310.00. The company has a market cap of $10.53 billion, a price-to-earnings ratio of 804.45, a PEG ratio of 2.83 and a beta of 0.51.
Penumbra (NYSE:PEN – Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The firm had revenue of $315.52 million during the quarter, compared to analysts’ expectations of $311.63 million. On average, equities analysts anticipate that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.
About Penumbra
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
See Also
- Five stocks we like better than Penumbra
- Trading Halts Explained
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- The Role Economic Reports Play in a Successful Investment Strategy
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What Are the U.K. Market Holidays? How to Invest and Trade
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.